Pharmaceutical

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue

Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.

Aug 11, 2024 - 04:00
Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue
Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.
Read the original article

Tags:

Previous Article

NICE supports Theramex’s Eladynos for post-menopause osteoporosis

Next Article

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Morning Rounds: Why some doctors plan to quit their jobs

Morning Rounds: Why some doctors plan to quit their jobs

Dec 19, 2023

FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease

FDA accepts Alpha Cognition’s NDA for Alzheimer’s disease

Dec 8, 2023

STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market

STAT+: Pharmalittle: Bioscience job market is upside do...

Nov 27, 2023